1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Oxcarbazepine |
| brand | String | Trileptal (IR), Oxtellar XR |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticonvulsants|Anticonvulsant]] • [[:Category:Mood stabilizers|Mood stabilizer (off-label)]] • [[:Category:Sodium channel blockers|Sodium channel blocker]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' |
| starting_dose | String | Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID |
| preparations | String | IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar) |
| fda_max | String | 2400 mg/day (adult) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Anticonvulsant effect within days at therapeutic plasma level |
| duration | String | BID dosing (IR); once-daily (XR) |
| halflife | String | Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)'"`UNIQ--ref-0000001A-QINU`"' |
| bioavailability | String | ~100% (oral)'"`UNIQ--ref-0000001B-QINU`"' |
| pregnancy | String | Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients'"`UNIQ--ref-0000001C-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
